At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Interferon alpha oral lozengedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
Texas Tech University Health Sciences Center·interventional·Posted Sep 29, 2011·Updated Apr 20, 2012
In Brief
A Phase 2 clinical trial evaluating Interferon alpha oral lozenge for Respiratory Tract Diseases and 3 related conditions. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Tract Diseases, Lung Diseases, Lung Diseases, Interstitial, Pulmonary Fibrosis
CountriesUnited States
CollaboratorsAinos, Inc. (f/k/a Amarillo Biosciences Inc.
Timeline
Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2000
Primary CompletionMay 2007
First PostedSep 2011
TodayJul 2026
First PostedSep 29, 2011
Enrollment StartSep 1, 2000
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 14.8 years ago
Interventions
Interferon alpha oral lozengedrug
dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year